511 results about "Treated patient" patented technology

The invention relates to the field of medical equipment, and provides a compact multi-chamber proton treatment system based on a shared beam line, and the system comprises a fixed beam transmission line which is used for guiding the movement direction of a proton beam into a vertical direction; the rotating beam transmission line is used for guiding the movement direction of the proton beam into the horizontal direction; one end of the fixed beam transmission line is connected with the proton cyclotron, the other end of the fixed beam transmission line is connected with one end of the rotary beam transmission line, and the other end of the rotary beam transmission line is in butt joint with a plurality of treatment rooms; the rotating beam transmission line rotates around a central axis extending in the vertical direction. According to the invention, the proton beam can be safely, efficiently and accurately transmitted to each treatment room, and a fixed beam transmission system and a rotating rack do not need to be independently arranged for each treatment room, so that the beam control assembly and the system occupied area of the multi-room particle treatment device are minimized, and the number of treated patients can be remarkably increased.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Provided are an INHBE gene-targeted double-stranded oligonucleotide, a conjugate, and a composition, which relate to the technical field of nucleic acid drugs. The double-stranded oligonucleotide comprises a sense strand and an antisense strand. The antisense strand is complementary or substantially complementary to the sense strand; the sense strand comprises a nucleotide sequence identical or substantially identical to at least 15 consecutive nucleotides in a sequence of SEQ ID NO: 309, and said substantially identical means that there is no more than three nucleotide differences between the sense strand and the at least 15 consecutive nucleotides in the sequence of SEQ ID NO: 309. The double-stranded oligonucleotide can effectively inhibit the INHBE gene and treat patients suffering from metabolic diseases or metabolic syndrome and related diseases such as diabetes, hypertension and cardiovascular diseases.

Provided are methods for identifying and treating patients with cancer, where the cancer expresses CEACAM5. The methods include measuring circulating CEA to identify patients likely to benefit from treatment with an agent specific for CEACAM5. Such patients can have high circulating CEA and only low or medium expression of CEACAM5 on tumor cells as measured by immunohistochemistry (IHC). The agent specific for CEACAM5 can be tusamitamab ravtansine. Such agent can be used in combination with one or more additional agents to treat the cancer. In certain embodiments the cancer is non-squamous non-small cell lung cancer (NSQ NSCLC).

The present invention relates to methods of treating patients with primary immunodeficiency diseases and disorders, using a CXCR4 inhibitor.

The present invention relates to methods of treating a human patient suffering from brain injury. These method may comprise (starting) administering to a selected patient within a time period of ≤12 hours or within a time period of >12 hours after the occurrence of the brain injury a therapeutically effective amount of a biopterin compound such as 4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin. The invention also relates to methods of increasing the value of the extended Glasgow Outcome Scale (eGOS) of patients suffering from brain injury, thereby improving the condition of the patient.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The present disclosure relates to methods of treating a patient that has a low coronary ostia height. The methods can involve advancing a heart valve prosthesis to a native valve structure having an ostium and positioning the prosthesis to align a gap between major peaks of the prosthesis with the ostium to avoid obstruction of the ostium. The presently disclosed methods and prostheses can be effective at treating patients with a coronary ostia height of as low as 10 mm, 8 mm, 6 mm, or less.

Introduced here are pressure-mitigation systems able to mitigate the pressure applied to a human body by the surface of an object (also referred to as a "structure") and assist a caretaker to move the human body. A controller device (or simply "controller") can be fluidically coupled to a pressure-mitigation device that includes a series of selectively inflatable chambers. When a pressure-mitigation device is placed between a human body and a surface, the controller can continuously, intelligently, and autonomously circulate fluid through the chambers of the pressure-mitigation device. Normally, the controller circulates air through the chambers of the pressure-mitigation device, though the controller could circulate another fluid, such as water or gel, through the chambers of the pressure-mitigation device. The controller may cause the chambers to be selectively inflated, deflated, or any combination thereof. As chambers selectively inflate, certain portions of the human body may be lifted above the surface, turned, or any combination thereof.

In various embodiments, provided herein are methods, devices and systems for transcatheter mitral valve replacement in a double-orifice mitral valve. These methods, devices and systems are used to treat patients with mitral valve disease, particularly those who have had failed edge-to-edge leaflet repair, or patients presently considered anatomically unsuitable for edge-to-edge leaflet repair alone.

The invention is applicable to the technical field of molecular biology, and provides a macrophage related gene KCNA3 and application thereof. The invention discloses a macrophage related gene KCNA3 for the first time, and the gene is identified as a macrophage related differential expression gene of a patient with type 2 diabetes mellitus with carotid atherosclerosis, and shows high expression in the patient with type 2 diabetes mellitus with carotid atherosclerosis. Through analysis of a public database transcriptome chip and high-throughput sequencing data and further verification of CIBERSORTX and WGCNA algorithms, close association between the KCNA3 gene and the macrophages is confirmed. Based on differentiated expression of the KCNA3 gene and correlation of the KCNA3 gene and macrophages, the gene can be used as a potential treatment target for further treating patients with the diabetes mellitus with the carotid atherosclerotic plaque, so that a new mechanism participating in disease progression of the diabetes mellitus with the carotid atherosclerotic plaque is disclosed.

The invention provides an artery plaque intracavitary directional rotary cutting device and a using method thereof, and belongs to the technical field of medical instruments. The arterial plaque intracavitary directional rotary cutting device comprises a tool bit protection sleeve, a medicine storage part, a windmill type rotary cutting tool bit, a hollow spiral-line-shaped long-strip net bag structure recycling net, a metal supporting net, a guide pipe and a control unit. On the basis of having the advantages of a plaque excision device in the prior art, the artery plaque intracavity directional rotary cutting device further has the following advantages that (1) the rotary cutting position is accurate; (2) the medicine is suitable for treating patients with femoral popliteal lesion and below-knee arteriosclerosis obliterans; (3) the operation cost and the operation risk are low; (4) the stimulation and trauma to a patient are small in an operation; (5) the rotary cutting depth is long; (6) the cut plaques and chippings can be prevented from falling off; (7) the restenosis progress of blood vessels can be delayed, and inflammatory response and immune response caused by operations can be relieved; and (8) the device is easy to clean after operation.

The disclosure relates to methods of assessing the success of treatment with durvalumab and chemotherapy for resectable non-small cell lung cancer (R-NSCLC) in patients based on circulating tumor DNA (ctDNA) detection, ctDNA clearance and / or partial clearance and / or variant allele fraction (VAF) before and after such treatment. The disclosure also relates to methods for treating patients with R-NSCLC based on ctDNA detection, ctDNA clearance and / or partial molecular clearance and / or VAF before and after such treatment.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Nicotine delivery devices and systems, particularly smoking cessation systems are provided by the present disclosure. Such devices and systems produce a nicotine-containing aerosol for inhalation that mimics smoking. The devices are capable of being adapted to control the amount of nicotine delivered to taper the amount of nicotine delivered to the user over time. Methods for treating patients to stop smoking are also disclosed. The devices, systems and methods can also be used to deliver other drugs disclosed herein, such as opioids (e.g., fentanyl).

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

Disclosed is a crystalline form of sepiapterin, a method of preparing the crystalline form, pharmaceutical compositions containing the crystalline form, and a method for treating patients with a disease associated with low intracellular BH4 levels or with dysfunction of various BH4 dependent metabolic pathways, which involves administering to the patient an effective amount of the crystalline form.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

Nicotine delivery devices and systems, particularly smoking cessation systems are provided by the present disclosure. Such devices and systems produce a nicotine-containing aerosol for inhalation that mimics smoking. The devices are capable of being adapted to control the amount of nicotine delivered to taper the amount of nicotine delivered to the user over time. Methods for treating patients to stop smoking are also disclosed. The devices, systems and methods can also be used to deliver other drugs disclosed herein, such as opioids (e.g., fentanyl).

The invention relates to an intelligent scheduling management platform system applied to the field of intelligent traffic, and when a 120 emergency command center sends a rescue to a traffic assistance platform, a bus closest to a rescue destination is dispatched to arrive at the position of a patient in advance, receives a citizen patient, then reversely runs along a running route of an ambulance, and converges with the ambulance, so that the rescue is completed. The problem that the patient cannot be treated in time due to the factors such as large traffic flow and long driving distance of an ambulance is effectively solved, the time for the patient to wait for treatment is shortened, the life safety of the patient is improved, and in addition, a medical passenger is carried to the position of the patient together through a bus, and after the patient is received, the patient can be timely treated. According to the invention, the medical passengers can carry out emergency treatment as needed on the patients, the life safety of the patients is further guaranteed, and in addition, the bus coupons are sent to the passengers getting off halfway due to the fact that the vehicles execute rescue tasks on the buses to make up for the passengers, so that the passengers can more actively cooperate with the rescue process.

The present invention addresses the problem of providing a novel therapeutic agent for treating patients with anti NMDAR encephalitis. Patients with an anti NMDAR encephalitis have a pathogenic anti-human NR1 antibody that induces internalization of NMDAR on cell surface. As a result, NMDAR function is weakened in the patients' brain. The present inventors found that the one-armed anti-human NR1 antibody according to the present invention binds to NR1 competitively with the pathogenic anti-human NR1 antibody and inhibits the internalization of NMDAR by the pathogenic anti-human NR1 antibody to thereby exhibit therapeutic effect on anti NMDAR encephalitis. Accordingly, the present invention provides a one-armed anti-human NR1 antibody, a polynucleotide encoding the antibody, an expression vector containing the polynucleotide, a host cell transformed by the expression vector, a method for producing the antibody, a pharmaceutical composition comprising the antibody, a use of the antibody in the manufacture of the pharmaceutical composition, and a method for treating anti NMDAR encephalitis using the antibody.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention relates to a breathing machine initial parameter setting method, and relates to the technical field of intelligent medical equipment.The method comprises the steps that the patient type and personal health medical data of a patient object are collected, the personal health medical data are input into a clustering classification model corresponding to the patient type to obtain a clustering category to which the patient object belongs, and the clustering category is classified; and setting the initial parameters of the breathing machine of the patient object based on the initial parameter data of each breathing machine of the historical treated patients in the clustering category of the patient object. Wherein the clustering classification model is obtained based on personal health medical data clustering learning of historical treatment patients under the patient type. Therefore, through the historical data, the respirator initial parameters of the historical treated patient closest to the personal health condition of the patient object are obtained, and the initial parameters most suitable for the patient object are obtained for setting, so that the empirical dependence on medical personnel is reduced, and meanwhile, the initial parameters with relatively high accuracy can be obtained based on the historical data; the medical effect is improved.

The present disclosure generally relates to artificial intelligence for robotic surgery. An apparatus for robotic surgery includes a processor configured with instructions to receive patient data from a treated patient, receive surgical robotic data for each of a plurality of treated patients, and output a treatment plan for the patient to be treated in response to the patient data and the surgical robotic data. The method has the advantage of adapting to individual variability and surgical system parameters among patients in order to provide improved treatment outcomes.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The augmented-reality automated allergy office method comprises initially delivering a trace amount of a first allergen to a first test site via a multiple test applicator as the multiple test applicator delivers a trace amount of a second allergen to a second test site during allergen deposition. The multiple test applicator is cooperatively engageable with a fluid tray during allergen loading and with the patient's skin during allergen deposition. Then, capturing a first image of the first and second test site using a smart phone or tablet computer. Subsequently, capturing a second image of the first and second test site within 15 to 20 minutes after allergen deposition. And finally, developing a computer-generated treatment plan using machine learning for the patient with an allergy condition that is a step-by-step procedure, the computer-generated treatment plan being stored in a medical database for treating patients with the allergy condition.

The present invention provides compounds of the formula:wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.

The invention is a method for treating patients with Parkinson's disease, primary parkinsonism / idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose “On” time or “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.